These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18309885)

  • 1. [Exon skipping in Duchenne's muscular dystrophy].
    Nau JY
    Rev Med Suisse; 2008 Jan; 4(140):176. PubMed ID: 18309885
    [No Abstract]   [Full Text] [Related]  

  • 2. Local dystrophin restoration with antisense oligonucleotide PRO051.
    van Deutekom JC; Janson AA; Ginjaar IB; Frankhuizen WS; Aartsma-Rus A; Bremmer-Bout M; den Dunnen JT; Koop K; van der Kooi AJ; Goemans NM; de Kimpe SJ; Ekhart PF; Venneker EH; Platenburg GJ; Verschuuren JJ; van Ommen GJ
    N Engl J Med; 2007 Dec; 357(26):2677-86. PubMed ID: 18160687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic administration of PRO051 in Duchenne's muscular dystrophy.
    Goemans NM; Tulinius M; van den Akker JT; Burm BE; Ekhart PF; Heuvelmans N; Holling T; Janson AA; Platenburg GJ; Sipkens JA; Sitsen JM; Aartsma-Rus A; van Ommen GJ; Buyse G; Darin N; Verschuuren JJ; Campion GV; de Kimpe SJ; van Deutekom JC
    N Engl J Med; 2011 Apr; 364(16):1513-22. PubMed ID: 21428760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challenge.
    Wood MJ
    Sci Transl Med; 2010 Mar; 2(25):25ps15. PubMed ID: 20424011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
    Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
    BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
    Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold?
    Guncay A; Yokota T
    Future Med Chem; 2015; 7(13):1631-5. PubMed ID: 26423833
    [No Abstract]   [Full Text] [Related]  

  • 8. Skipping toward personalized molecular medicine.
    Hoffman EP
    N Engl J Med; 2007 Dec; 357(26):2719-22. PubMed ID: 18160693
    [No Abstract]   [Full Text] [Related]  

  • 9. Exon skipping, a therapy for Duchenne muscular dystrophy. Interview by Guenter Scheuerbrandt.
    Platenburg G
    Acta Myol; 2008 Oct; 27():69-73. PubMed ID: 19364065
    [No Abstract]   [Full Text] [Related]  

  • 10. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
    Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
    Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Exon skipping approach to Duchenne muscular dystorphy].
    Takeda S
    Rinsho Shinkeigaku; 2014; 54(12):1071-3. PubMed ID: 25672711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy.
    Hammond SM; Wood MJ
    Curr Opin Mol Ther; 2010 Aug; 12(4):478-86. PubMed ID: 20677099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons.
    Aartsma-Rus A; Kaman WE; Weij R; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Mol Ther; 2006 Sep; 14(3):401-7. PubMed ID: 16753346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of Duchenne muscular dystrophy by induction of skipping of dystrophi exon].
    Matsuo M; Yagi M; Takeshima Y
    Rinsho Shinkeigaku; 2006 Nov; 46(11):936-8. PubMed ID: 17432225
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic modulation of DMD splicing by blocking exonic splicing enhancer sites with antisense oligonucleotides.
    Aartsma-Rus A; Janson AA; Heemskerk JA; De Winter CL; Van Ommen GJ; Van Deutekom JC
    Ann N Y Acad Sci; 2006 Oct; 1082():74-6. PubMed ID: 17145928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Casimersen (Amondys 45) for Duchenne muscular dystrophy.
    Med Lett Drugs Ther; 2021 Jun; 63(1627):e104-e105. PubMed ID: 34181634
    [No Abstract]   [Full Text] [Related]  

  • 17. The therapeutic potential of antisense-mediated exon skipping.
    van Ommen GJ; van Deutekom J; Aartsma-Rus A
    Curr Opin Mol Ther; 2008 Apr; 10(2):140-9. PubMed ID: 18386226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
    Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exon-skipping therapy for Duchenne muscular dystrophy.
    Nakamura A; Takeda S
    Lancet; 2011 Aug; 378(9791):546-7. PubMed ID: 21784507
    [No Abstract]   [Full Text] [Related]  

  • 20. 194th ENMC international workshop. 3rd ENMC workshop on exon skipping: towards clinical application of antisense-mediated exon skipping for Duchenne muscular dystrophy 8-10 December 2012, Naarden, The Netherlands.
    Aartsma-Rus A; Muntoni F
    Neuromuscul Disord; 2013 Nov; 23(11):934-44. PubMed ID: 23890933
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.